Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects

Cancer Immunology, Immunotherapy

Volumn 57, Issue 8, 2008, Pages 1173-1183

  Chakraborty, Mala ^a   Gelbard, Alexander ^b   Carrasquillo, Jorge A ^c   Yu, Sarah ^d   Mamede, Marcelo ^d   Paik, Chang H ^d   Camphausen, Kevin ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Immunotherapy; mAb; Radiation; Vaccine; Y 90

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; COL 1 MONOCLONAL ANTIBODY Y 90; FAS ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP 70; MONOCLONAL ANTIBODY; PROTEIN P53; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL TRANSPLANTATION; CELL VIABILITY; CELLULAR IMMUNITY; COLON ADENOCARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; ISOTOPE LABELING; LYMPHOCYTE COUNT; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; HEMATOLOGIC NEOPLASMS; MICE; MICE, TRANSGENIC; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; UP-REGULATION; YTTRIUM RADIOISOTOPES;

EID: 44249097814     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0449-x     Document Type: Article

References (46)

1. Brooks PC, Roth JM, Lymberis SC, DeWyngaert K, Broek DFormenti SC (2002) Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis. Int J Radiat Oncol Biol Phys 54(4):1194-1201
2. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JAEconomou JS (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9(3):998-1008
3. Cavacini LA, Duval M, Eder JPPosner MR (2002) Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin Cancer Res 8(2):368-373
4. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CNHodge JW (2003) Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170(12):6338-6347
5. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom JHodge JW (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64(12):4328-4337
6. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SARestifo NP (1996) Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 56(12):2832-2836
7. Demaria S, Bhardwaj N, McBride WHFormenti SC (2005) Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63(3):655-666
8. Eades-Perner AM, van der Putten H, Hirth A, Thompson J, Neumaier M, von Kleist SZimmermann W (1994) Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 54(15):4169-4176
9. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman MEisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29(10):3295-3301
10. Ganss R, Ryschich E, Klar E, Arnold BHammerling GJ (2002) Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62(5):1462-1470
11. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom JHodge JW (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64(21):7985-7994
12. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43(5):693-713
13. Grayson JM, Harrington LE, Lanier JG, Wherry EJAhmed R (2002) Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol 169(7):3760-3770
14. Hallahan D, Kuchibhotla JWyble C (1996) Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 56(22):5150-5155
15. Hilburger Ryan M Abrams SI (2001) Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 49(11):603-612
16. Hodge JW, McLaughlin JP, Kantor JASchlom J (1997) Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15(6-7):759-768
17. Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz LSchlom J (2000) Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 92(15):1228-1239
18. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MGSchlom J (1999) A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59(22):5800-5807
19. Horning SJ (2003) Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 30(6 Suppl 17):29-34
20. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DMJaffee EM (1996) The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93(18):9730-9735
21. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SARestifo NP (1997) Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 89(21):1595-1601
22. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh GWahl RL (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4):1259-1266
23. Kass E, Panicali DL, Mazzara G, Schlom JGreiner JW (2001) Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61(1):206-214
24. Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC (2005) Radioimmunotherapy and colorectal cancer. Br J Surg 92(3):264-276
25. Kudo-Saito C, Schlom JHodge JW (2005) Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 11(6):2416-2426
26. Kuroki M, Greiner JW, Simpson JF, Primus FJ, Guadagni FSchlom J (1989) Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies. Int J Cancer 44(2):208-218
27. Lacabanne V, Viguier M, Guillet JGChoppin J (1996) A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 26(11):2635-2639
28. Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JMWiltrout RH (2000) IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 164(1):231-239
29. Markiewicz MA, Fallarino F, Ashikari AGajewski TF (2001) Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 13(5):625-632
30. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KYSchlom J (2000) Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18(23):3964-3973
31. Modrak DE, Gold DV, Goldenberg DMBlumenthal RD (2003) Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy. Tumour Biol 24(1):32-39
32. Muraro R, Wunderlich D, Thor A, Lundy J, Noguchi P, Cunningham RSchlom J (1985) Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 45(11 Pt 2):5769-5780
33. Nikitina EY Gabrilovich DI (2001) Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94(6):825-833
34. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JARobinson BW (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170(10):4905-4913
35. Pilon SA, Kelly CWei WZ (2003) Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 170(3):1202-1208
36. Press OW (2003) Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 30(2 Suppl 4):10-21
37. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SEFisher RI (2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102(5):1606-1612
38. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PDSchlom J (1991) Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51(14):3657-3662
39. Rosato A, Santa SD, Zoso A, Giacomelli S, Milan G, Macino B, Tosello V, Dellabona P, Lollini PL, De Giovanni CZanovello P (2003) The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res 63(9):2158-2163
40. Ryschich E, Harms W, Loeffler T, Eble M, Klar ESchmidt J (2003) Radiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat. Int J Cancer 105(4):506-511
41. Sharkey RM Goldenberg DM (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46(Suppl 1):115S-127S
42. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver JColcher D (2000) High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 6(8):3095-3102
43. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver JColcher D (1997) High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol 15(4):1518-1528
44. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani PWhite CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20(10):2453-2463
45. Yang JC Perry-Lalley D (2000) The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J Immunother 23(2):177-183
46. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa RMelief CJ (2002) Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 62(21):6187-6193